Vident Investment Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

Vident Investment Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-23,847	Closed	-$4.38M	–	1280
2021 Q2	$4.38M	Buy	23,847 +2,145	+10%	+$368K	0.13%	148
2021 Q1	$3.32M	Buy	+21,702	New	+$3.36M	0.11%	171
2020 Q4	–	Sell	-31,524	Closed	-$3.61M	–	936
2020 Q3	$3.61M	Buy	31,524 +17,596	+126%	+$1.9M	0.18%	105
2020 Q2	$1.56M	Buy	13,928 +7,296	+110%	+$775K	0.08%	293
2020 Q1	$596K	Buy	+6,632	New	+$651K	0.04%	532
2018 Q2	–	Sell	-3,780	Closed	-$416K	–	997
2018 Q1	$416K	Sell	3,780 -4,302	-53%	-$514K	0.02%	690
2017 Q4	$966K	Buy	8,082 +17	+0.2%	+$2.07K	0.04%	382
2017 Q3	$1.13M	Buy	+8,065	New	+$1.1M	0.06%	350
2015 Q3	–	Sell	-19	Closed	-$3K	–	1177
2015 Q2	$3K	Buy	+19	New	+$3.28K	﹤0.01%	1054

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return